AOD-9604 — hGH C-terminal fragment lipid-metabolism research

AOD-9604 is one of the more carefully characterised fragments in the human-growth-hormone research literature: a 16-residue C-terminal synthetic peptide whose published pharmacology is concentrated almost entirely on adipocyte lipid metabolism. Its history runs from a Monash University laboratory in the 1990s through a structured preclinical development program and a series of in-vitro and animal-model lipolysis-research studies that establish what the molecule does and, importantly, what remains unresolved about how it does it.

What AOD-9604 actually is

AOD-9604 (the original development code assigned by Metabolic Pharmaceuticals; the chemical-research literature uses the AOD-9604 designation directly) is a synthetic peptide corresponding to amino-acid residues 177-191 of the human growth hormone sequence, with a tyrosine residue appended at the N-terminus to facilitate radiolabelling in the original research. The native fragment is 15 residues; the synthetic AOD-9604 with the N-terminal Tyr is 16 residues, with a molecular weight of approximately 1,815 Da. The internal disulphide bridge between the cysteines at positions equivalent to hGH 182 and 189 is preserved.

The fragment was identified through structure-activity work in the Monash University laboratory of Frank Ng and colleagues, who established in the 1990s that the C-terminal end of the hGH molecule retains a distinct pharmacological profile when separated from the full hormone — specifically, the lipid-metabolism activity of the parent hormone is largely retained while the somatogenic and insulin-modulating activities are not. AOD-9604 was synthesised as a defined version of this C-terminal pharmacology.

What the mechanism research shows

The published preclinical pharmacology converges on three findings:

• Stimulation of lipolysis. The Heffernan 2001 paper in Endocrinology documents that AOD-9604 increases lipolysis in adipose tissue in animal models, with the magnitude of the lipolytic response comparable to that produced by intact human growth hormone — and reports that this lipolytic action is not mediated through the β3-adrenergic receptor [1].
• A defined lipolytic domain of hGH, without somatogenic activity. Ng and colleagues (2000, Hormone Research) characterised AOD-9604 as a synthetic lipolytic domain of human growth hormone, establishing that the C-terminal fragment carries the lipid-metabolic activity of the parent hormone while lacking its somatogenic profile — it does not drive the growth and IGF-1 effects of the full hormone [2].
• Signalling independent of the growth-hormone receptor. Heffernan and colleagues (2001) report that AOD-9604 does not compete for the growth-hormone receptor in binding assays and does not produce growth-hormone-receptor-mediated cell proliferation, yet still drives its lipid-metabolism effects — direct evidence that the fragment acts through a pathway distinct from canonical growth-hormone-receptor signalling [3].

That receptor finding is the most interesting point in the literature: the fragment carries a clear lipid-metabolism action, but the receptor it acts through has not been positively identified. The negative result (not the canonical growth-hormone receptor, not the β3-adrenergic receptor) is well documented; the positive identification of the actual pathway is not.

Honest take: the lipolysis pharmacology of AOD-9604 is reasonably well-replicated in animal-model and cell-based work. The receptor through which it acts is still not positively identified in peer-reviewed work — an unusual and interesting situation for a peptide that has been in research circulation for over two decades.

The development history

Metabolic Pharmaceuticals advanced AOD-9604 through a structured preclinical program in the late 1990s and early 2000s, including a series of company-sponsored clinical-pharmacology studies. The molecule received GRAS (Generally Recognized As Safe) status from a US ingredient-regulatory perspective for non-pharmaceutical use, which is what allowed its subsequent appearance in research-supply and adjacent markets — but GRAS classification is a food-ingredient regulatory status, not a medicinal-product approval, and AOD-9604 has never been approved as a medicine by the FDA, EMA, or any equivalent regulator.

From a research-grade-supply standpoint, the development history is relevant context for two reasons. First, the in-vitro pharmacology was characterised by the original developer to a higher standard than is typical for the research-peptide category. Second, the absence of any clinical-product approval means that all clinical claims about the compound are extrapolations from the in-vitro and animal-model data, not conclusions from human RCTs.

The UAE research-supply landscape

AOD-9604 is supplied in the UAE as a lyophilised powder, most commonly 5 mg per vial. The disulphide-linked structure makes the synthesis slightly more demanding than equivalent-length linear peptides, so research-supply purity-control practice varies meaningfully across vendors. The compound is reasonably stable in dry form at -20°C and is typically rated for 28 days at 2-8°C after reconstitution in bacteriostatic water.

Open questions

The questions the published literature has not yet answered:

• Receptor identification. The standard GHR is apparently not the signalling target for the AOD-9604 lipid-metabolism effects; the alternative pathway has been hypothesised but not definitively characterised.
• Human pharmacokinetics. The half-life, distribution, and metabolism in humans have been investigated in company-sponsored work but the public peer-reviewed pharmacokinetic record is thin.
• In-vivo translation. The robust in-vitro adipocyte lipolysis findings have a more variable record when translated to in-vivo animal models — the lipid-metabolism endpoints reported in cell-culture do not always reproduce at equivalent magnitudes in whole-animal preparations.
• Long-term safety. Multi-year administration data does not exist in the published literature. The GRAS classification is based on short-term studies and a specific regulatory pathway, not on long-term clinical follow-up.

AOD-9604 research cluster — deeper dives

Three companion deep-dives go under this overview:

• AOD-9604 mechanism research — the lipolytic-domain concept, lipolysis comparable to intact hGH but not via the β3-adrenergic receptor, the growth-hormone-receptor-independent signalling, and the unidentified pathway.
• AOD-9604 research evidence and regulatory status — what the preclinical record establishes, the in-vitro-to-in-vivo gap, GRAS food-ingredient status (not a medicine), and the WADA prohibited-in-sport position.
• AOD-9604 dosing research protocols — the internal-disulphide-bridge handling nuance, what the studies administered (no validated human dose), reconstitution, and storage.

Further reading

Peer-reviewed citations used inline:

• [1] Heffernan et al. — Endocrinology 2001. Lipolytic action of AOD-9604 in animal models, comparable to intact hGH and not mediated by the β3-adrenergic receptor.
• [2] Ng et al. — Hormone Research 2000. Metabolic characterisation of the synthetic lipolytic domain (AOD-9604) of human growth hormone.
• [3] Heffernan et al. — 2001. Receptor-binding and cell-proliferation assays showing AOD-9604 does not compete for the growth-hormone receptor — evidence of a signalling pathway distinct from the canonical GH receptor.

Last reviewed 26 May 2026. Wellness Labs supplies AOD-9604 as research-grade lyophilised powder for non-clinical investigation. Editorial inbox: info@uaewellnesslab.com.